Nexalin Technology, Inc. announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia treated with the Company’s high-power 15 mA, 77.5 Hz stimulation approach. The paper was published online on April 20, 2026.
The study, titled: “Modulating Default and Salience/Ventral Attention networks: Exploring the treatment effect of transcranial alternating current stimulation on chronic insomnia,” evaluated the effects of four weeks of active treatment using Nexalin’s DIFS technology versus sham devices in a randomized, double-blind, sham-controlled trial. According to the publication, patients in the active treatment group experienced a statistically significant reduction in Pittsburgh Sleep Quality Index (PSQI) scores from 13.8 to 7.7 (p < 0.001), while the sham group showed no significant change, with PSQI scores moving from 13.8 to 13.9 (p = 0.74).
The publication also reported that treatment was associated with measurable modulation of neural activity and functional connectivity in primary brain networks implicated in hyperarousal, emotional regulation, and self-referential processing, including the Default and Salience/Ventral Attention networks. The authors concluded that the findings provide insight into the potential mechanism of response by which Nexalin’s proprietary frequency stimulation improves the functional health of the brain, which also improves sleep quality in individuals with chronic insomnia.
“This publication represents another important scientific validation point for Nexalin and our proprietary DIFS™ technology,” said Dr. David Owens, Chief Medical Officer of Nexalin Technology. “We believe these findings go beyond simply suggesting symptom improvement; they also provide neuroimaging evidence indicating that our high-power, non-invasive approach may be modulating key brain networks. This combination of clinical signal and mechanistic support further strengthens the case for Nexalin’s treatment platform and reinforces the broader potential of DIFS™ across neuropsychiatric indications.”
“We believe Nexalin DIFS™ represents a breakthrough in neurostimulation technology,” said Mark White, Chief Executive Officer of Nexalin Technology. “Unlike conventional approaches that may be limited by power, invasiveness, tolerability, or depth of engagement, DIFS™ is designed to deliver a differentiated, high-power, non-invasive stimulation approach that is undetectable to the human body. We believe Nexalin has the potential to meaningfully advance the standard of care for mental health. Based on the growing body of clinical and scientific evidence, we believe DIFS™ stands apart from currently available neurostimulation techniques and may offer a superior platform for addressing complex brain-based disorders. Nexalin continues to advance the HALO™ Clarity pivotal program with a growing body of peer-reviewed evidence that supports the unique value proposition of Nexalin technology for patients, providers, and shareholders.”
The newly published paper adds to Nexalin’s expanding body of clinical literature across insomnia and other neuropsychiatric indications. Nexalin previously announced positive published insomnia data from a 120-participant randomized, double-blind, placebo-controlled multicenter study, and in February and April 2026 announced its pivotal HALO™ Clarity trial intended to support a planned De Novo FDA submission in insomnia.
Source Nexalin
